报价延迟最少15分钟:2026/01/09 18:18 EST
盘后时段
|
||||
|
3.81 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.7
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.51/-0.38
|
|
企业价值
436.95M
|
| 资产负债 |
|
每股账面净值
1.71
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
-221,563,000
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B). |
